DBV Technologies (DBVT) Expected to Announce Earnings on Tuesday

DBV Technologies (NASDAQ:DBVT - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, July 29th. Analysts expect DBV Technologies to post earnings of ($0.28) per share and revenue of $0.64 million for the quarter.

DBV Technologies Stock Performance

Shares of DBVT traded up $0.27 during midday trading on Thursday, hitting $9.74. The company had a trading volume of 2,809 shares, compared to its average volume of 226,556. The company's 50-day simple moving average is $9.56 and its 200-day simple moving average is $7.16. The firm has a market capitalization of $266.78 million, a P/E ratio of -1.98 and a beta of -0.59. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78.

Analysts Set New Price Targets

DBVT has been the subject of a number of recent analyst reports. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. HC Wainwright lifted their price target on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 5th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price target for the company in a report on Thursday, May 29th. Finally, Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $14.75.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.